Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Blood (2018) 132 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2018-99-110149

Published: 2018

Journal Articles

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

Blood (2017) 130 (Supplement 1): 4331.

https://doi.org/10.1182/blood.V130.Suppl_1.4331.4331

Published: 2017

Journal Articles

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

Karen Menezes, PhD BSc, MSc, Grace Aram, MSc, Fabio Mirabella, PhD, David C Johnson, PhD, Amy L Sherborne, PhD, Richard S Houlston, MD PhD, Matthew D Cheeseman, PhD, Elisa Pasqua, PhD, Paul Clarke, PhD, Paul Workman, PhD, Keith Jones, PhD, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 3072.

https://doi.org/10.1182/blood.V130.Suppl_1.3072.3072

Published: 2017

Journal Articles

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Blood (2017) 130 (Supplement 1): 396.

https://doi.org/10.1182/blood.V130.Suppl_1.396.396

Published: 2017

Journal Articles

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Blood (2016) 128 (22): 804.

https://doi.org/10.1182/blood.V128.22.804.804

Published: 2016

Journal Articles

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

Blood (2016) 128 (22): 4407.

https://doi.org/10.1182/blood.V128.22.4407.4407

Published: 2016

Journal Articles

Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases

Martin F Kaiser, MD, Eileen Mary Boyle, MD PhD, Brian A Walker, PhD, Dil B Begum, Paula Proszek, David C Johnson, PhD, Charlotte Pawlyn, MB BChir, John R Jones, MD, Suvi Savola, PhD, Roger G Owen, Mark T Drayson, MD PhD, David A Cairns, Gordon Cook, MD PhD, Walter M Gregory, Richard S Houlston, MDPhDFRCP, Faith E Davies, MD, Graham H Jackson, MD, Gareth J Morgan, MD PhD

Blood (2015) 126 (23): 2981.

https://doi.org/10.1182/blood.V126.23.2981.2981

Published: 2015

Journal Articles

Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients

Blood (2015) 126 (23): 2983.

https://doi.org/10.1182/blood.V126.23.2983.2983

Published: 2015

Journal Articles

Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

Blood (2015) 126 (23): 371.

https://doi.org/10.1182/blood.V126.23.371.371

Published: 2015

Journal Articles

High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation

Martin F Kaiser, MD, Alexander Murison, PhD, Charlotte Pawlyn, MBBChir, Eileen M Boyle, MD, David C Johnson, PhD, Brian A Walker, PhD, Ping Wu, MBBS, MSc, Dil Begum, BSc, Nasrin Dahir, BSc, Christopher P Wardell, PhD, Paula Proszek, MSc, David A Cairns, PhD, Walter Gregory, PhD, Graham Jackson, MD, Roger G Owen, MD, Gordon Cook, MD PhD, Mark T Drayson, MDPhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD

Blood (2014) 124 (21): 2189.

https://doi.org/10.1182/blood.V124.21.2189.2189

Published: 2014

Journal Articles

The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact

Blood (2014) 124 (21): 2194.

https://doi.org/10.1182/blood.V124.21.2194.2194

Published: 2014

Journal Articles

Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma

Blood (2014) 124 (21): 723.

https://doi.org/10.1182/blood.V124.21.723.723

Published: 2014

Journal Articles

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

Blood (2014) 124 (21): 637.

https://doi.org/10.1182/blood.V124.21.637.637

Published: 2014

Journal Articles

The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment

Blood (2014) 124 (21): 640.

https://doi.org/10.1182/blood.V124.21.640.640

Published: 2014

Journal Articles

High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients

Martin F Kaiser, MD, Eileen M Boyle, MD, Brian A Walker, PhD, Charlotte Pawlyn, MBBChir, Dil Begum, BSc, Paula Proszek, MSc, Nasrin Dahir, BSc, David C Johnson, PhD, Suvi Savola, PhD, David A Cairns, PhD, Walter Gregory, PhD, Graham Jackson, MD, Roger G Owen, MD, Gordon Cook, MD PhD, Mark T Drayson, MDPhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD

Blood (2014) 124 (21): 172.

https://doi.org/10.1182/blood.V124.21.172.172

Published: 2014

Journal Articles

Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA

Martin F Kaiser, MD, Paula Proszek, MSc, Dil Begum, BSc, Nasrin Dahir, BSc, Brian A Walker, PhD, Suvi Savola, PhD, Eileen M Boyle, MD, David C Johnson, PhD, David A Cairns, PhD, Walter Gregory, PhD, Graham Jackson, MD, Roger G Owen, MD, Gordon Cook, MD PhD, Mark T Drayson, MDPhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2014) 124 (21): 5168.

https://doi.org/10.1182/blood.V124.21.5168.5168

Published: 2014

Journal Articles

Expression Quantitative Trait Loci Reveal Regulatory Regions Important In The Pathogenesis of Multiple Myeloma

Blood (2013) 122 (21): 1847.

https://doi.org/10.1182/blood.V122.21.1847.1847

Published: 2013

Journal Articles

MYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over-Expression and Decreased Overall Survival

Brian A Walker, PhD, Christopher P Wardell, PhD, Dil Begum, BSc, Nasrin Dahir, BSc, David C Johnson, PhD, Faith E Davies, MD, Gareth J Morgan, MD, PhD

Blood (2013) 122 (21): 274.

https://doi.org/10.1182/blood.V122.21.274.274

Published: 2013

Journal Articles

Discovery Of Genome Wide Epigenetic Programming In t(4;14) Multiple Myeloma and In The Progression From Myeloma To Plasma Cell Leukemia Via Methyl Binding Domain Protein Capture and Sequencing

Martin F Kaiser, MD, Alexander Murison, PhD, Christopher P Wardell, PhD, David C Johnson, PhD, Charlotte Pawlyn, MD, Fabio Mirabella, PhD, Lorenzo Melchor, PhD, Kerry Fenwick, Iwanka Kozarewa, PhD, Faith E Davies, MD, Brian A Walker, PhD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 599.

https://doi.org/10.1182/blood.V122.21.599.599

Published: 2013

Journal Articles

Single-Cell Genetic Analysis Reveals The Genetic Composition Of Founder Clones, Phylogenetic Patterns Of Branching and Parallel Evolution, and Clonal Fluctuations Following Patient Treatment In Multiple Myeloma

Lorenzo Melchor, PhD, Annamaria Brioli, MD, Christopher P Wardell, PhD, Alexander Murison, PhD, Nicola E Potter, PhD, Martin F Kaiser, MD, Rosemary A Fryer, PhD, David C Johnson, PhD, Dil Begum, BSc, Sanna Hulkki, Gowri Vijayaraghavan, Ian Titley, PhD, Michele Cavo, MD, Faith E Davies, MD, Brian A Walker, PhD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 398.

https://doi.org/10.1182/blood.V122.21.398.398

Published: 2013

NARROW

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases

Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients

Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation

The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact

Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment

High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients

Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA

Expression Quantitative Trait Loci Reveal Regulatory Regions Important In The Pathogenesis of Multiple Myeloma

MYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over-Expression and Decreased Overall Survival

Discovery Of Genome Wide Epigenetic Programming In t(4;14) Multiple Myeloma and In The Progression From Myeloma To Plasma Cell Leukemia Via Methyl Binding Domain Protein Capture and Sequencing

Single-Cell Genetic Analysis Reveals The Genetic Composition Of Founder Clones, Phylogenetic Patterns Of Branching and Parallel Evolution, and Clonal Fluctuations Following Patient Treatment In Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only